Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00531778 · ClinicalTrials.gov registry record
NYU Ovarian Cancer Early Detection Program Blood and Genetics
A clinical trial, sponsored by NYU Langone Health.
- Terminated
- Registry status
- 890
- Enrollment target
NCT00531778 is a clinical trial that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 890 participants.
The verdict
NCT00531778 was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- 890 participants
- Enrollment target
Study Summary
Improving current strategies for detection of early stage disease can impact favorably on long-term survival of women with ovarian cancer. To reduce the morbidity and mortality of ovarian cancer, screening for this disease must detect early stage disease rather than advanced stage disease. Thus the challenge for the future is to identify and develop highly sensitive and specific tumor markers that can be applied to population-based screening for the early detection of ovarian cancer.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 890 participants |
| Start Date | 2004-06 |
| Est. Completion | 2010-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00531778
The ClinicalTrials.gov registry entry for NCT00531778 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 890 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00531778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00531778 about?
NCT00531778 is a clinical study titled "NYU Ovarian Cancer Early Detection Program Blood and Genetics". Improving current strategies for detection of early stage disease can impact favorably on long-term survival of women with ovarian cancer. To reduce the morbidity and mortality of ovarian cancer, screening for this disease must detect early stage disease rather than advanced stage disease. Thus the ...
What is the current status of trial NCT00531778?
This trial is currently terminated. The enrollment target is 890 participants. The study started on 2004-06. Estimated completion is 2010-11.
Who is sponsoring clinical trial NCT00531778?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.